The mutation of the CDKN2A gene is extremely rare (3%), and its presence associated with clinical evolution has led some researchers to consider these tumors as an intermediate between IDH wildtype and mutant IDH glioblastoma [14]. The gene discussed is IDH1; the disease is glioblastoma.